Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis.
Jashin J WuChing An WangGreeta JobsonDavid DavidsonSamaneh KaliraiJulia ZhuManasi SuryavanshiMayank MittalVardhaman PatelLauren SeigelPublished in: The Journal of dermatological treatment (2023)
< 0.001), primarily attributable to pharmacy costs: $3466 (apremilast), $4432 (tumor necrosis factor inhibitor), and $4721 (interleukin inhibitor).